Psoriatic Arthritis

A recent study identified the prevalence of asymptomatic pulmonary involvement in patients with newly diagnosed RA or PsA, highlighting the need to reevaluate screening protocols.

Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.

After 16 weeks of treatment, a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response.

The COSMOS trial showed guselkumab every 8 weeks improved PsA outcomes through week 48, including in patients with inadequate responses to TNF inhibitors.

A prospective study also found that the presence of psoriasis and dactylitis at disease onset were the strongest predictors for the development of PsA.

Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.

Findings from PsABIOnd can help reassure clinicians of similar efficacy between treatment choices.

The findings are especially important as differences in disease characteristics and outcomes between male and female patients become more clear.

This post-hoc analysis demonstrated an association between work productivity and stringent disease control criteria for those with psoriatic arthritis.

These data, presented at ACR 2024, demonstrate that response was maintained at 2 years among those with psoriatic arthritis who responded to bimekizumab at Week 16.

People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.

People with diabetes, kidney stones, damaged joints, high uric acids, and daily use of NSAID were more likely to develop CKD than others.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

The international phase 4 MOSAIC study is the first evaluating PsAMRIS and MRI-WIPE outcomes in patients with psoriatic arthritis.

The rheumatology month in review emphasizes new data on secukinumab, gout clinical decision making, and addressing sleep issues in fibromyalgia.

Patients exposed to screening were also more likely to receive vaccinations and consult a cardiologist and/or a pneumologist.

Malignancy-related IBP has distinct features: shorter diagnosis time, higher ESR/CRP/LDH, lower hemoglobin, and often involves metastasis or paraneoplastic causes.

The new administration options allow a single-injection option for patients that require a 320 mg dose.

Of patients randomized to guselkumab Q8W, 93% to 99% maintained minimally clinically important improvements in joint disease through 1 year.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.

Secukinumab is best for severe skin involvement, while adalimumab improves synovitis in PsA. Both are effective, but larger studies are needed for long-term outcomes.

An interim analysis of the PRO-SPIRIT study compared outcomes at 3 months after starting new treatments for psoriatic arthritis.

The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.

A greater portion of patients treated with bimekizumab achieved minimal clinically important differences than with placebo.

Concomitantly, other treatment modalities such as physical and occupational therapy, anticonvulsants, topical analgesics, and psychosocial treatment have increased.

BIMZELX was previously approved for treating moderate-to-severe plaque psoriasis.

Gender, age, and disease duration significantly affected symptom variations.

Extended follow-up with more cases is ongoing and will allow risk factors for psoriatic arthritis to also be further explored.

There were also no significant differences in clinical parameters at baseline for patients initiating first-line or not first-line therapy.